Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, ValuEngine reports.
Separately, Maxim Group restated a “buy” rating and issued a $9.00 price target on shares of Brainstorm Cell Therapeutics in a research report on Friday, November 15th.
Shares of BCLI stock opened at $5.16 on Thursday. Brainstorm Cell Therapeutics has a fifty-two week low of $3.43 and a fifty-two week high of $6.67. The business has a fifty day simple moving average of $4.27 and a 200-day simple moving average of $3.94.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). As a group, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -0.93 earnings per share for the current fiscal year.
In other news, CFO Preetam Shah purchased 11,600 shares of the company’s stock in a transaction dated Tuesday, December 24th. The stock was acquired at an average price of $4.12 per share, for a total transaction of $47,792.00. Company insiders own 21.20% of the company’s stock.
Several hedge funds have recently made changes to their positions in BCLI. BlackRock Inc. increased its position in Brainstorm Cell Therapeutics by 44.6% during the 2nd quarter. BlackRock Inc. now owns 130,281 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 40,197 shares in the last quarter. Virtu Financial LLC purchased a new stake in Brainstorm Cell Therapeutics during the 3rd quarter worth about $51,000. Phoenix Holdings Ltd. purchased a new stake in Brainstorm Cell Therapeutics during the 3rd quarter worth about $138,000. CFO4Life Group LLC purchased a new stake in Brainstorm Cell Therapeutics during the 4th quarter worth about $51,000. Finally, Tower Research Capital LLC TRC increased its position in Brainstorm Cell Therapeutics by 1,640.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,155 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 10,514 shares in the last quarter. Institutional investors and hedge funds own 9.41% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
See Also: Trade War
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.